REDWOOD CITY, Calif.,
Jan. 7, 2019 /PRNewswire/
-- Genomic Health, Inc. (NASDAQ: GHDX) today
announced that, in collaboration with physicians around the world,
it has delivered more than 1 million Oncotype DX® tests
to cancer patients worldwide since it made its first test available
to patients in 2004. To date, more than 53,000 physicians across 90
countries have used Oncotype DX to optimize treatment decisions for
their breast, prostate and colon cancer patients. Use of Oncotype
DX is helping deliver on the promise of precision medicine by
improving outcomes for cancer patients around the world, while
saving healthcare systems more than $5
billion globally to date.
"In 2004, I was the first patient in the world to use the
Oncotype DX test to guide my chemotherapy treatment decision," said
Katherine Young, a breast cancer
survivor. "Standard assessments indicated that chemotherapy would
be necessary for my treatment. However, based on my Oncotype DX
Breast Recurrence Score result, my physician and I made the
decision to forgo chemotherapy and its side effects. Fourteen years
later, I am confident in my treatment choice and proud to be one of
the million people who have benefited from Oncotype DX
testing."
"With millions of cancer patients around the world, it is
critical to be able to individualize care. Oncotype DX tests have
paved the way for precision medicine by providing personalized
information based on the unique biology of every cancer, and by
enabling confident, individualized treatment decisions. Genomic
testing has become a mainstream component of cancer care, and
patients are seeing the benefits through improved outcomes," said
Harold A. Burstein, M.D., Ph.D., medical oncologist at
the Dana-Farber Cancer Institute.
Genomic Health's portfolio of Oncotype DX tests is supported by
a significant amount of clinical evidence, including 125 clinical
studies involving 140,000 patients and more than 150 journal
publications. Recently, the landmark TAILORx trial was published.
This trial used the Oncotype DX Breast Recurrence Score®
to define, with precision, the individual benefit of chemotherapy
for early-stage breast cancer patients.
"We founded Genomic Health with the goal of improving the
quality of treatment decisions for cancer patients by ending a 'one
size fits all approach' with individualized and actionable genomic
information to guide critical treatment decisions," said
Steven Shak, M.D., co-founder and
chief scientific officer, Genomic Health. "Our collaborations with
physicians around the world, grounded in rigorous science with a
focus on health outcomes, have now spared more than 1 million
cancer patients from either over-treatment or under-treatment of
their disease."
About Oncotype DX®
The Oncotype DX® portfolio of breast, colon and prostate
cancer tests applies advanced genomic science to reveal the unique
biology of a tumor in order to optimize cancer treatment decisions.
The company's flagship product, the Oncotype DX Breast Recurrence
Score® test, is the only test that has been shown to
predict the likelihood of chemotherapy benefit as well as
recurrence in invasive breast cancer. Additionally, the Oncotype DX
Breast DCIS Score test predicts the likelihood of recurrence in a
pre-invasive form of breast cancer called DCIS. In prostate cancer,
the Oncotype DX Genomic Prostate Score® test
predicts disease aggressiveness and further clarifies the current
and future risk of the cancer prior to treatment intervention, and
the Oncotype DX AR-V7 Nucleus Detect™ test helps
determine which patients with metastatic castration-resistant
prostate cancer (mCRPC) are resistant to androgen receptor
(AR)-targeted therapies. The Oncotype DX AR-V7 Nucleus Detect test
is performed by Epic Sciences at its centralized, CLIA-certified
laboratory in San Diego and
offered exclusively by Genomic Health. With more than 1 million
patients tested in more than 90 countries, the Oncotype DX tests
have redefined personalized medicine by making genomics a critical
part of cancer diagnosis and treatment. To learn more about
Oncotype DX tests, visit www.OncotypeIQ.com,
www.MyBreastCancerTreatment.org or
www.MyProstateCancerTreatement.org.
About Genomic Health
Genomic Health, Inc.
(NASDAQ: GHDX) is the world's leading provider of genomic-based
diagnostic tests that help optimize cancer care, including
addressing the overtreatment of the disease, one of the greatest
issues in healthcare today. With its Oncotype
IQ® Genomic Intelligence Platform, the company is
applying its world-class scientific and commercial expertise and
infrastructure to lead the translation of clinical and genomic big
data into actionable results for treatment planning throughout the
cancer patient journey, from diagnosis to treatment selection and
monitoring. The Oncotype IQ portfolio of genomic tests and services
currently consists of the company's flagship line of Oncotype
DX® gene expression tests that have been used to
guide treatment decisions for over 1 million cancer patients
worldwide. Genomic Health is expanding its test portfolio
to include additional liquid- and tissue-based tests, including the
recently launched Oncotype DX® AR-V7 Nucleus Detect™
test. The company is based in Redwood City, California, with
international headquarters in Geneva, Switzerland. For
more information, please visit, www.GenomicHealth.com and
follow the company on
Twitter: @GenomicHealth, Facebook, YouTube and LinkedIn.
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995, including statements relating to the benefits of Oncotype DX
tests to physicians, patients and payors. Forward-looking
statements are subject to risks and uncertainties that could cause
actual results to differ materially, and reported results should
not be considered as an indication of future performance. These
risks and uncertainties include, but are not limited to: the
results of clinical studies, including the TAILORx study; the
applicability of clinical study results to actual outcomes; the
ability of the test results to change treatment decisions and
improve patient outcomes; the risks and uncertainties associated
with the regulation of the company's tests; the risk that the
company may not obtain or maintain sufficient levels of
reimbursement, domestically or abroad, for its existing tests and
any future tests it may develop; the risks of competition;
unanticipated costs or delays in research and development efforts;
and the other risks set forth in the company's filings with the
Securities and Exchange Commission, including the risks set forth
in the company's Quarterly Report on Form 10-Q for the quarter
ended September 30, 2018. These
forward-looking statements speak only as of the date hereof.
Genomic Health disclaims any obligation to update these
forward-looking statements.
NOTE: The Genomic Health logo, Oncotype, Oncotype DX, Breast
Recurrence Score, DCIS Score, Genomic Prostate Score, GPS, Oncotype
DX AR-V7 Nucleus Detect and Oncotype IQ are trademarks or
registered trademarks of Genomic Health, Inc. All other trademarks
and service marks are the property of their respective
owners.
GHDX-F
View original content to download
multimedia:http://www.prnewswire.com/news-releases/genomic-health-marks-more-than-1-million-patients-worldwide-who-have-benefited-from-oncotype-dx-testing-in-personalizing-cancer-treatment-decisions-to-improve-outcomes-300773224.html
SOURCE Genomic Health, Inc.